News

May 19, 2017

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Cytokinetics Receives FDA Orphan Drug Designation for CK-2127107 for SMA

Cytokinetics, Inc. recently announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CK-2127107, a next-generation fast skeletal muscle activator, for the potential treatment of spinal muscular...

READ MORE   |  

Topics: Clinical Trials, Front Page News

April 24, 2017

Biogen Releases New Data from Cherish and Nurture Trials

Biogen Releases New Data from Cherish and Nurture Trials

Biogen will present Phase 3 end of study SPINRAZA® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in children with later-onset (most likely to develop Type 2 or Type 3) spinal muscular atrophy...

READ MORE   |  

Topics: Clinical Trials, Front Page News

March 29, 2017

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA

Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open to...

READ MORE   |  

Topics: Clinical Trials, Front Page News

Items 1 - 3 of 92  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software